medigraphic.com
ISSN 2500-7106 (Electronic)
ISSN 0123-2576 (Print)
Medicina & Laboratorio

2021, Number 4

<< Back Next >>

Medicina & Laboratorio 2021; 25 (4)

Detection of isocitrate dehydrogenase enzyme mutation in grades II, III and IV diffuse gliomas

Naranjo-Botero P, Medina-Zuluaica LA, Muñetón-Peña CM, Arango-Viana JC, Ospina-Ospina S

Language: Spanish
References: 31
Page: 709-719
PDF size: 966.49 Kb.


ABSTRACT

Introduction. Gliomas are the most common primary malignancies of the central nervous system, associated with high mortality and morbidity. Mutations in the isocitrate dehydrogenase (IDH) enzyme IDH1 and IDH2 genes, are key in tumorigenesis, and are considered an important prognostic factor in these neoplasms. This study aimed to determine the presence of IDH1 and IDH2 gene mutations in patients diagnosed with diffuse glioma in different degrees, and their correlation with survival. Methodology. A descriptive, prospective and retrospective study was conducted. The study population consisted of patients between the ages of 18 and 45 with a diagnosis of grade II, III and IV diffuse glioma, treated at the Hospital San Vicente Fundación in Medellín, between 2012 and 2017, in whom an analysis of IDH1 and IDH2 gene mutations was performed by Sanger sequencing and immunohistochemical staining. Results. Fourteen patients with a mean age of 37 years were included, 57% were male. Glioblastoma was the most frequent neoplasm, diagnosed in 42.9% of the cases. By immunohistochemistry, 10 of the 14 (71.4%) patients had a mutation of the IDH1 enzyme, while 1 of the 11 (9%) patients in whom IDH2 gene sequencing was achieved showed a mutation. In general, 78.6% had IDH enzyme mutations, with an average survival of 48 months. Conclusion. These findings suggest that gliomas are a heterogeneous group of tumors, with great genetic variability that impacts their prognosis and behavior.


REFERENCES

  1. Ostrom QT, Patil N, Cioffi G, Waite K, KruchkoC, Barnholtz-Sloan JS. CBTRUS statisticalreport: Primary brain and other central nervoussystem tumors diagnosed in the United Statesin 2013-2017. Neuro Oncol 2020;22:1-96.https://doi.org/10.1093/neuonc/noaa200.

  2. International Agency for Research on Cancer.Colombia fact sheet. Source: GLOBOCAN2020. Lyon, France: IARC; 2020. Acceso 15 deabril de 2021. Disponible en https://gco.iarc.fr/today/data/factsheets/populations/170-colombia-fact-sheets.pdf.

  3. Louis DN, Ohgaki H, Wiestier OD, CaveneeWK, Ellison DW, Figarella-branger D, et al.WHO classification of tumours of the centralnervous system. Ginebra, Suiza: InternationalAgency for Research on Cancer; 2016. 4th.

  4. Kemel AG, George EB, Valentina E, JannethG, Rosa HB, Magdy S, et al. Gliomas:New perspectives in diagnosis, treatment andprognosis. Curr Top Med Chem 2017;17:1438-1447. https://doi.org/10.2174/1568026617666170103162639.

  5. Parsons DW, Jones S, Zhang X, Lin JC, LearyRJ, Angenendt P, et al. An integrated genomicanalysis of human glioblastoma multiforme.Science 2008;321:1807-1812. https://doi.org/10.1126/science.1164382.

  6. Yan H, Parsons DW, Jin G, McLendonR, Rasheed BA, Yuan W, et al. IDH1 andIDH2 mutations in gliomas. N Engl J Med2009;360:765-773. https://doi.org/10.1056/NEJMoa0808710.

  7. Ichimura K. Molecular pathogenesis of IDHmutations in gliomas. Brain Tumor Pathol2012;29:131-139. https://doi.org/10.1007/s10014-012-0090-4.

  8. Hartmann C, Meyer J, Balss J, Capper D,Mueller W, Christians A, et al. Type and frequencyof IDH1 and IDH2 mutations are relatedto astrocytic and oligodendroglial differentiationand age: a study of 1,010 diffuse gliomas.Acta Neuropathol 2009;118:469-474. https://doi.org/10.1007/s00401-009-0561-9.

  9. Lee SC. Diffuse gliomas for nonneuropathologists:The new integrated molecular diagnostics.Arch Pathol Lab Med 2018;142:804-814.https://doi.org/10.5858/arpa.2017-0449-RA.

  10. Reiter-Brennan C, Semmler L, Klein A. Theeffects of 2-hydroxyglutarate on the tumorigenesisof gliomas. Contemp Oncol (Pozn)2018;22:215-222. https://doi.org/10.5114/wo.2018.82642.

  11. Han CH, Batchelor TT. Isocitrate dehydrogenasemutation as a therapeutic target in gliomas.Chin Clin Oncol 2017;6:33. https://doi.org/10.21037/cco.2017.06.11.

  12. Figueroa ME, Abdel-Wahab O, Lu C, Ward PS,Patel J, Shih A, et al. Leukemic IDH1 and IDH2mutations result in a hypermethylation phenotype,disrupt TET2 function, and impair hematopoieticdifferentiation. Cancer Cell 2010;18:553-567. https://doi.org/10.1016/j.ccr.2010.11.015.

  13. Waitkus MS, Diplas BH, Yan H. Isocitrate dehydrogenasemutations in gliomas. Neuro Oncol2016;18:16-26. https://doi.org/10.1093/neuonc/nov136.

  14. Aoki K, Natsume A. Overview of DNAmethylation in adult diffuse gliomas. BrainTumor Pathol 2019;36:84-91. https://doi.org/10.1007/s10014-019-00339-w.

  15. Ricaurte O, Neita K, Valero D, Ortega-Rojas J,Arboleda-Bustos CE, Zubieta C, et al. Estudiode mutaciones en los genes IDH1 e IDH2 enuna muestra de gliomas de población colombiana.Biomédica 2018;38:86-92. https://doi.org/10.7705/biomedica.v38i0.3708.

  16. Gondim DD, Gener MA, Curless KL, Cohen-Gadol AA, Hattab EM, Cheng L. DeterminingIDH-mutational status in gliomas using IDH1-R132H antibody and polymerase chain reaction.Appl Immunohistochem Mol Morphol2019;27:722-725. https://doi.org/10.1097/pai.0000000000000702.

  17. Li J, Zhang H, Wang L, Yang C, Lai H, ZhangW, et al. Comparative study of IDH1 mutationsin gliomas by high resolution melting analysis,immunohistochemistry and direct DNA sequencing.Mol Med Rep 2015;12:4376-4381.https://doi.org/10.3892/mmr.2015.3987.

  18. Yang W, Warrington NM, Taylor SJ, WhitmireP, Carrasco E, Singleton KW, et al. Sex differencesin GBM revealed by analysis of patientimaging, transcriptome, and survival data. SciTransl Med 2019;11:eaao5253. https://doi.org/10.1126/scitranslmed.aao5253.

  19. Gómez-Vega JC, Ocampo-Navia MI, Feo-LeeO. Epidemiología y caracterización general delos tumores cerebrales primarios en el adulto.Univ Med 2019;60:47-60.

  20. Kaminska B, Czapski B, Guzik R, Król SK,Gielniewski B. Consequences of IDH1/2mutations in gliomas and an assessment ofinhibitors targeting mutated IDH proteins.Molecules 2019;24. https://doi.org/10.3390/molecules24050968.

  21. Agarwal S, Sharma MC, Jha P, Pathak P,Suri V, Sarkar C, et al. Comparative study ofIDH1 mutations in gliomas by immunohistochemistryand DNA sequencing. Neuro Oncol2013;15:718-726. https://doi.org/10.1093/neuonc/not015.

  22. Bustamante JA, Astudillo M, Pazos AJ, BravoLE. Evaluación de dos métodos de extracciónde adn a partir de biopsias fijadas en formalinay embebidas en parafina en condiciones noóptimas. Acta Biol Colomb 2011;16:83-98.

  23. Amemiya K, Hirotsu Y, Oyama T, Omata M.Relationship between formalin reagent andsuccess rate of targeted sequencing analysisusing formalin fixed paraffin embedded tissues.Clin Chim Acta 2019;488:129-134. https://doi.org/10.1016/j.cca.2018.11.002.

  24. Nuovo G. False-positive results in diagnosticimmunohistochemistry are related tohorseradish peroxidase conjugates in commerciallyavailable assays. Ann Diagn Pathol2016;25:54-59. https://doi.org/10.1016/j.anndiagpath.2016.09.010.

  25. Olar A, Wani KM, Alfaro-Munoz KD, HeathcockLE, van Thuijl HF, Gilbert MR, et al. IDHmutation status and role of WHO grade and mitoticindex in overall survival in grade II-III diffusegliomas. Acta Neuropathol 2015;129:585-596.https://doi.org/10.1007/s00401-015-1398-z.

  26. Scott JN, Rewcastle NB, Brasher PM, FultonD, MacKinnon JA, Hamilton M, et al. Whichglioblastoma multiforme patient will become along-term survivor? A population-based study.Ann Neurol 1999;46:183-188.

  27. Donson AM, Birks DK, Schittone SA, Kleinschmidt-DeMasters BK, Sun DY, HemenwayMF, et al. Increased immune gene expressionand immune cell infiltration in high-grade astrocytomadistinguish long-term from short-termsurvivors. J Immunol 2012;189:1920-1927.https://doi.org/10.4049/jimmunol.1103373.

  28. Gerber NK, Goenka A, Turcan S, ReyngoldM, Makarov V, Kannan K, et al. Transcriptionaldiversity of long-term glioblastoma survivors.Neuro Oncol 2014;16:1186-1195. https://doi.org/10.1093/neuonc/nou043.

  29. Peng S, Dhruv H, Armstrong B, Salhia B, LegendreC, Kiefer J, et al. Integrated genomicanalysis of survival outliers in glioblastoma.Neuro Oncol 2017;19:833-844. https://doi.org/10.1093/neuonc/now269.

  30. Burgenske DM, Yang J, Decker PA, KollmeyerTM, Kosel ML, Mladek AC, et al. Molecularprofiling of long-term IDH-wildtype glioblastomasurvivors. Neuro Oncol 2019;21:1458-1469.https://doi.org/10.1093/neuonc/noz129.

  31. Sonoda Y. Clinical impact of revisions to theWHO classification of diffuse gliomas andassociated future problems. Int J Clin Oncol2020;25:1004-1009. https://doi.org/10.1007/s10147-020-01628-7.




2020     |     www.medigraphic.com